Clinical trials: Obinutuzumab, open to volunteers
Minimal Change Disease (MCD)
A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)
OBELIX-NEPHROSIS (NS) The goal of this clinical trial is to learn if obinutuzumab works to treat minimal change disease in adults. It will also learn about the safety of drug obinutuzumab.
- Trial name
- OBELIX-NS (NCT07710157)
- Testing
- Obinutuzumab Injection, Predniso(lo)ne
- Where
- 6 sites in Austria, France and 1 more
- Volunteers
- 48 people
- Sponsor
- Medical University Innsbruck
Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL)
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
This is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic…
- Trial name
- VTB-CLL002 (NCT06762431)
- Testing
- Lenalidomide, Obinutuzumab Injection [Gazyva]
- Where
- Belarus
- Volunteers
- 24 people
- Sponsor
- Vitebsk Regional Clinical Cancer Centre
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT06849713
- Testing
- Zanubrutinib, Sonrotoclax, Obinutuzumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation
Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma
This prospective, open-label, Phase II clinical trial evaluates the efficacy and safety of pirtobrutinib combined with sotoclax across three distinct B-cell lymphoma cohorts: histologically transformed diffuse large B-cell…
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation, CLL / SLL, MZL
- Trial name
- NCT07744750
- Testing
- Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changzhou No.2 People's Hospital
Lupus Nephritis
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
- Trial name
- NCT07611214
- Testing
- LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA)
- Where
- 27 sites in United States
- Volunteers
- 150 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL)
Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
- Trial name
- NCT06967610
- Testing
- Pirtobrutinib, Venetoclax, Obinutuzumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Lupus Nephritis, Membranous Nephropathy
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
Lupus nephritis (LN) is a frequent and severe complication of systemic lupus erythematosus, with important mortality and morbidity.
- Trial name
- OBLUMEN (NCT07721363)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or…
- Trial name
- NCT06765317
- Testing
- Glofitamab, Polatuzumab, Rituximab
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Mantle Cell Lymphoma (MCL)
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
This study aims to evaluate the safety and efficacy of orelabrutinib (O) in combination with obinutuzumab (G) and short-course venetoclax (V) in patients with treatment-naïve MCL.
- Trial name
- NCT07719556
- Testing
- Orelabrutinib, Obinutuzumab, Venetoclax
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Follicular Lymphoma ( FL)
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
This study intends to conduct a prospective, multicenter, open-label, randomized controlled clinical trial to systematically evaluate the efficacy and safety of the orelabrutinib plus obinutuzumab and lenalidomide (RO2) regimen…
- Trial name
- NCT07719855
- Testing
- Orelabrutinib, obinutuzumab, Lenalidomide
- Where
- China
- Volunteers
- 652 people
- Sponsor
- Ruijin Hospital
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (GemOx) versus standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell…
- Trial name
- NCT07599423
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- China
- Volunteers
- 96 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lymphoma, Mantle-Cell
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
This open-label, multicenter, three cohorts, phase II study is designed to assess a combination of Zanubrutinib/Venetoclax/Glofitamab or Venetoclax/Glofitamab in high-risk subjects with either first line or R/R Mantle Cell…
- Trial name
- GLOASIS (NCT06558604)
- Testing
- Obinutuzumab, Glofitamab, Venetoclax Oral Product
- Where
- 16 sites in Belgium, France
- Volunteers
- 100 people
- Sponsor
- The Lymphoma Academic Research Organisation
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β
An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy
This clinical trial aims to evaluate the safety and efficacy of obinutuzumab β in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The key research objectives are as follows:1.
- Trial name
- NCT07696377
- Testing
- Obinutuzumab β
- Volunteers
- 24 people
- Sponsor
- Zhongming Qiu
Chronic Lymphocytic Leukemia
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
This is a single-arm, open-label Phase 2 study designed to evaluate the treatment outcomes of nemtabrutinib-venetoclax-obinutuzumab as a frontline management for chronic lymphocytic leukemia (CLL).
- Trial name
- NCT07690891
- Testing
- Nemtabrutinib, Venetoclax, Obinutuzumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Richter Syndrome
Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome
This is a national clinical trial, multicentric (28 centers), non-randomized phase 2 study. Population: Patients with previously untreated Richter's syndrome (RS), defined as the occurrence of an aggressive lymphoma (of diffuse…
- Trial name
- GLORIFY (NCT06186648)
- Testing
- Glofitamab + Obinutuzumab
- Where
- 23 sites in France
- Volunteers
- 40 people
- Sponsor
- French Innovative Leukemia Organisation
Chronic Lymphocytic Leukemia
A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
The goal of this clinical research study is to learn if the combination of zanubrutinib, sonrotoclax, and obinutuzumab can help to control previously untreated CLL/SLL.
- Trial name
- NCT07674810
- Testing
- Zanubrutinib, Obinutuzumab, Sonrotoclax
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The goal of this phase II randomized open label study is to compare the rate of complete remission (CR) with undetectable minimal residual disease (uMRD) obtained with zanubrutinib in combination with obinutuzumab with two…
- Trial name
- NCT06544785
- Testing
- Zanubrutinib Oral Product, Obinutuzumab
- Where
- 19 sites in Spain
- Volunteers
- 106 people
- Sponsor
- PETHEMA Foundation
Relapsed /Refractory DLBCL
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
The goal of this clinical trial is to see if a new combination of standard of care radiotherapy treatment prior to administering the study drugs obinutuzumab and glofitamab in relapsed/refractory Diffuse Large B Cell Lymphoma…
- Trial name
- Radio-GLO (NCT07634289)
- Testing
- Glofitamab, Radiotherapy, Obinutuzumab
- Where
- 5 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
CLL (Chronic Lymphocytic Leukemia)
Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
The evidence base in support of fixed-duration, first-line approaches in medically fit patients with CLL is clearly strengthening, whether through combining targeted agents with immunochemotherapy or through chemotherapy-free…
- Trial name
- PACIFIC (NCT07624799)
- Testing
- Pirtobrutinib, Fludarabine, Cyclophosphamide
- Volunteers
- 82 people
- Sponsor
- French Innovative Leukemia Organisation
Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
This study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
- Trial name
- NCT07613788
- Testing
- Rimegepant, Glofitamab, Obinutuzumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital